Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carlumab + docetaxel
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Carlumab + docetaxel is a combination therapy consisting of **carlumab**, a human monoclonal antibody targeting CC-chemokine ligand 2 (CCL2), and **docetaxel**, a microtubule inhibitor. Carlumab blocks CCL2, a chemokine involved in tumor growth, metastasis, and chemoresistance, potentially enhancing antitumor immune responses and reducing tumor-associated macrophage recruitment. Docetaxel disrupts microtubule assembly, inhibiting cell division and inducing apoptosis in cancer cells. This combination has been investigated in phase 1 trials for patients with advanced solid tumors, aiming to overcome chemoresistance and improve antitumor efficacy[2][5][6].
- Brand names
- TaxotereDocefrezACT DOCEtaxelDOCEtaxelTaro-DOCEtaxel
- Other names
- carlumab + docetaxelCNTO 888 + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))CCL2 (C-C motif chemokine 2)
Beyond the preview
Go deeper on carlumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carlumab + docetaxel.